FDA Adds Chengdu Shengnuo Biopharm to Import Alert 66-40 Red List

The FDA Import Alert 66-40 page lists Chengdu Shengnuo Biopharm Co., Ltd. of Chengdu, Sichuan, China, on the Red List with the date published of September 19, 2026. Every product entry for the firm on that page reads 'All Drugs and Drug Products,' with the same date of September 19, 2026.

Import Alert 66-40 is titled 'Detention Without Physical Examination of Drugs From Firms Which Have Not Met Drug GMPs.' The alert states that it represents the agency's current guidance to FDA field personnel, that divisions may detain covered drugs without physical examination, and that the charge rests on methods and controls that do not appear to conform to current good manufacturing practices.

Secondary reporting in September and October 2026 connected this firm to peptide active pharmaceutical ingredients, including semaglutide and tirzepatide material. This connection is reported here as secondary reporting, not as a statement on the FDA Red List page itself, which lists the firm for all drugs and drug products without naming a peptide.

Detention under an import alert is a border action, not a product approval decision, and not a finding about any single batch. The FDA page does not state that every shipment was examined or that every batch was found contaminated.

This post is flagged in the backfill manifest as a borderline item verified directly on fda.gov. The verification is the Red List entry itself: firm name, alert number, and date published September 19, 2026, as read on the official FDA import alert page.